Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
21 Setembro 2023 - 8:30AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines, today announced that Connie Collingsworth, former Chief
Operating Officer of the Bill and Melinda Gates Foundation, will
join the Company’s Business Advisory Board (BAB). The BAB was
established in June 2023 to assist in driving public/private
partnerships with governments around the world; pursuing business
collaborations, partnerships, and licensing opportunities; creating
awareness of the Company’s differentiated capabilities; and
promoting access to the Company’s therapies around the world.
“Connie brings value-added expertise in all aspects of strategic
growth and organizational governance—across a variety of
industries—that will offer unique insights to the BAB,” said Dr.
Shankar Musunuri, Chairman, CEO and Co-founder of Ocugen. “Connie’s
deep financial background at a global level will provide meaningful
counsel to Ocugen as we pursue new business development
opportunities to support and evolve our clinical programs.”
Ms. Collingsworth has been a primary advisor to Bill Gates,
Melinda French Gates, and Warren Buffett regarding governance.
During her tenure with the Bill and Melinda Gates Foundation, she
designed and implemented the core operational infrastructure and
created the intellectual property strategy known as “Global
Access,” as well as advising on the creation of a $2.5 billion
strategic investment fund.
“I am inspired by Ocugen’s commitment to not only developing
novel therapies that address unmet medical needs for patients with
serious conditions, but their passion to ensure access to all
patients around the world,” said Ms. Collingsworth. “I look forward
to sharing my diverse experiences as an executive and a board
member so that patients can potentially benefit.”
Ms. Collingsworth joins Senator Pat Toomey, Ambassador Joseph W.
Westphal, Ph.D., and Dennis Carey, Ph.D. on the BAB. These advisors
will work alongside the Executive Leadership Team to offer guidance
to enable the Company to fulfill its mission and achieve its short-
and long-term strategy.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patient’s lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on Twitter and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks, and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact:Tiffany
HamiltonHead of Corporate
CommunicationsTiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ocugen (NASDAQ:OCGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024